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Abstract 
Post-translational protein modifications are critical regulators of protein 
functions as they expand the signaling potentials of the modified proteins, leading 
to diverse physiological consequences. Currently, increasing evidence suggests 
that protein methylation is as important as other post-translational modifications in 
the regulation of various biological processes. This drives us to ask whether 
methylation is involved in the EGFR (epidermal growth factor receptor) signaling, 
a biological process extensively regulated by multiple post-translational 
modifications including phosphorylation, glycosylation and ubiquitination. We 
found that EGFR R1175 is methylated by a protein arginine methyltransferase 
named PRMT5. During EGFR activation, PRMT5-mediated R1175 methylation 
 v
specifically enhances EGF-induced EGFR autophosphorylation at Y1173 residue. 
This novel modification crosstalk increases SHP1 recruitment to EGFR and 
suppresses EGFR-mediated ERK activation, resulting in inhibition of cell 
proliferation, migration, and invasion of EGFR-expressing cells. Based on these 
findings, we provide the first link between arginine methylation and tyrosine 
phosphorylation and identify R1175 methylation as an inhibitory modification 
specifically against EGFR-mediated ERK activation. 
 vi
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CHAPTER 1  INTRODUCTION 
 
1.1 EGFR signaling and its biological effects  
The epidermal growth factor receptor (EGFR) is a transmembrane 
cell-surface receptor of the ErbB (erythroblastic leukemia viral oncogene homolog) 
receptor tyrosine kinase family consisting of ErbB1 (EGFR), ErbB2 (Her2), ErbB3 
and ErbB4. It is composed of an extracellular domain that provides ligand-binding 
sites, a single transmembrane domain and a cytosolic region that contains a 
juxtamembrane domain, a tyrosine kinase domain and a C-terminal tail segment[1, 
2] (Figure 1). As a cell surface receptor, EGFR is able to convert extracellular 
cues into intracellular effectors, leading to specified cellular responses. A general 
accepted theory of EGFR activation is that binding of ligands, including EGF 
(epidermal growth factor), TGF-(transforming growth factor-), HB-EGF 
(heparin-binding EGF-like growth factor), AREG (amphiregulin), BTC 
(betacellulin), EPG (epigen) and EPR (epiregulin) to the EGFR extracellular 
domains causes structural change of the domains, exposure of dimerization arms 
and induces dimerization of two receptor monomers[2-6]. EGFR can form either 
homo-dimers or hetero-dimers with other family members[2, 7, 8]. Receptor 
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dimerization leads to activation of intrinsic tyrosine kinase domains[9] and 
subsequent autophosphorylations on multiple tyrosine (Y) residues of the 
C-terminal tail segments, including Y992, Y1045, Y1068, Y1086, Y1148 and 
Y1173[10] (Figure 1). These tyrosine phosphorylations create docking motifs for 
different cytosolic signaling molecules containing SH2 (Src homology 2) and PTB 
(phosphotyrosine binding) domains[11]. Through recruiting these molecules, 
EGFR initiates several downstream signaling cascades including the RAS 
-RAF-MEK-ERK pathway (Ras, rat sarcoma viral oncogene homologue; RAF, 
v-raf murine sarcoma viral oncogene homologue; MEK, MAPK/ERK activator 
kinase; ERK, extracellular signal-regulated kinase), the PI3K-AKT pathway (PI3K, 
phosphoinositide 3-kinase), the PLC-PKC pathway (PLC , phospholipase C- 
PKC, protein kinase C) and the STATs (signal transducer and activator of 
transcription) pathway (Figure 1). These signalings finally culminate in cell 
proliferation, migration, adhesion, invasion, cell cycle progression and 
differentiation[4, 12-14].  
EGFR has been shown to play important roles in development. In genetically 
engineered mouse models, mice lacking EGFR die within the first month of birth 
and multiple developmental defects can be observed in mammary duct, skin,  
 3
Figure 1. The EGFR signaling. Schematic representation of the functional 
domains of EGFR, the tyrosine (Y) phosphorylations induced by ligand stimulation 
and the downstream signaling cascades activated by recruiting cytosolic signaling 
molecules to the phospho-tyrosine residues. Red arrows indicate bindings 
between the phospho-tyrosines and the cytosolic molecules. 
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central nervous system, lung, pancreas and gastrointestinal tract[15-20]. EGFR 
has also been linked to stem cell renewal and proliferation[21-26]. Besides, 
aberrant EGFR activation caused by EGFR gene amplification, mutation and/or 
ligand overexpression is involved in the pathogenesis and progression of various 
cancer types, especially breast cancer, lung cancer and colon cancer[12, 27-36]. 
 
1.2 Regulation of EGFR signaling by post-translational modifications  
Post-translation modifications (PTMs) play central roles in the activation and 
regulation of EGFR signaling. As mentioned above, ligand-stimulated EGFR 
tyrosine autophosphorylations are essential to transmit extracellular stimuli into 
intracellular responses. Each of the phospho-tyrosines and its flanking amino acid 
residues form a peptide motif to selectively bind the SH2 or PTB domains of one 
or more cytosolic signaling molecules. Similarly, with very few exceptions, each of 
the cytosolic signaling molecules binds EGFR through more than one 
phospho-tyrosine with different affinities[37-40] (Figure 1). Given that different 
ligand stimulations or dimerization partners can induce different tyrosine 
phosphorylation patterns on EGFR[41-43]. This redundancy in binding sites 
between phospho-tyrosines and cytosolic signaling molecules allows the 
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activation of various downstream signaling cascades to be combinatorially 
regulated by different stimulation conditions or cellular contents[38, 39]. In 
addition to the positive roles in initiating EGFR downstream signalings, 
autophosphorylated tyrosine residues also mediate inhibitory mechanisms 
against EGFR activity. One well-characterized example is Y1045, which serves as 
a docking site for Cbl (Casitas B-cell lymphoma), the primary E3 ubiquitin ligase of 
EGFR. Recruitment of Cbl to EGFR through phosphorylated Y1045 promotes 
receptor ubiquitination and degradation, resulting in downregulation of EGFR 
activity[44]. Receptor with defective Y1045 phosphorylation escapes from 
Cbl-induced ubiquitination and degradation[45-47]. 
Many other kinases also involve in the EGFR signaling through directly 
phosphorylating EGFR. Some of the best known include: growth 
hormone-activated JAK2 (Janus kinase 2) can phosphorylate EGFR at Y1068 and 
specifically trigger EGFR-mediated ERK activation [48]. Src phosphorylates 
EGFR at Y845 and Y1101, resulting in enhanced receptor signaling[49]. 
Serine/threonine phosphorylation by PKC, ERK and CaMKII 
(calmodulin-dependent protein kinase II) modulates receptor tyrosine kinase 
activity and internalization[50-52].  
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Besides phosphorylation, EGFR is also subjected to non-phosphorylation 
post-translational modifications. One of the well-known is N-glycosylation of the 
EGFR extracellular domain, which is essential for the maturation and membrane 
transport of nascent receptor, and for the ligand binding activity of mature surface 
receptor[53-57]. Moreover, the E3 ubiquitin ligase Cbl-mediated ubiquitination and 
neddylation have been demonstrated as a primary attenuation mechanism of 
EGFR signaling. Both modifications coordinately serve as sorting signals to 
promote lysosomal degradation of activated EGFR and control the duration of 
EGFR activation[58-63]. Recently identified acetylation of EGFR further expands 
the content of EGFR PTM network as acetylation was demonstrated to enhance 
endocytosis or tyrosine phosphorylation of the receptor[64, 65].  
 
1.3 Protein arginine methylation in regulating cellular processes  
Protein arginine methylation is a post-translational modification that adds 
one or two methyl groups to the guanidino nitrogen atoms of arginine. Methyl 
groups can be added to the internal () or the terminal () nitrogen atoms. So far, 
-NG-methylarginine residues have been observed only in Saccharomyces 
cerevisiae. In eukaryotes, three types of methylarginine have been identified, 
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including -NG-monomethylarginines (MMA), -NG, NG-asymmetric 
dimethylarginines (aDMA), and -NG, N'G-symmetric dimethylarginines (sDMA) 
[66-68] (Figure 2).  
Arginine is a positively charged amino acid important in mediating hydrogen 
bonding and amino-aromatic interactions. Although methylation does not change 
the overall charge of an arginine residue, addition of methyl groups removes 
amino hydrogens that be involved in hydrogen bonds and increases steric 
hindrance. Therefore, arginine methylation may inhibit intra- or inter-molecular 
interactions. On the other hand, arginine methylation can also act as a positive 
regulator of protein-protein interactions. The Tudor domain has been recognized 
as a methyl-binding protein structure motif specifically recognizing di-methyl 
arginines. Several Tudor domain-containing proteins have been shown to interact 
with their binding partners in a methylarginine-dependent manner[69-71]. Besides 
protein-protein interactions, arginine methylation may modulate protein function 
through regulating the subcellular localization of targeting proteins[72-75]. 
Through these regulatory mechanisms, arginine methylation has been shown to 
be involved in transcriptional regulation, RNA processing, signaling transduction 
and DNA damage repair[67, 68, 76, 77].  
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Figure 2. Arginine methylation and the protein arginine methyltransferase 
(PRMT) family. Monomethylarginine (MMA) can be generated by all types of 
PRMTs. Type I and type II PRMTs further catalyze the formation of asymmetric 
dimethylarginine (aDMA) and symmetric dimethylarginine (sDMA), respectively. 
S-adenosyl methionine (AdoMet) is the methyl group donor and converted into 
S-adenosyl homocysteine (AdoHcy) after reactions.  
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1.4 Protein arginine methyltransferases (PRMTs), demethylase and 
deiminase 
Protein arginine methylation is mediated by enzymes of the protein arginine 
N-methyltransferase (PRMT) family. All family members share a core arginine 
methyltransferases region which catalyze the transfer of a methyl group from the 
methyl donor, S-adenosyl methionine (AdoMet) to arginine[67, 68, 76-78]. PRMT 
members are further classified into four major groups according to the type of 
methylarginine they generate. Type I, II and III PRMTs methylate the terminal () 
guanidino nitrogen atoms. Type I and type II PRMTs both catalyze the formation of 
MMA, and type I PRMTs further catalyze the production of aDMA, whereas type II 
PRMTs catalyze the formation of sDMA. Type III PRMTs catalyze only MMA 
(Figure 2). Besides, type IV PRMTs methylate the internal () guanidino nitrogen 
atom of arginine[67, 68, 76, 77]. 
Currently, ten mammalian PRMTs have been identified within which PRMT1, 
3, 4, 6 and 8 belong to type I PRMTs, whereas PRMT5, 7 and FBXO11 exhibit 
type II enzymatic activity. In addition, PRMT7 also shows type III activity on certain 
substrates. On the contrary, no activity has been demonstrated for PRMT2 and 
PRMT9, and no type IV enzyme has been identified in mammals to date [67, 68, 
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77] (Figure 2). Proteins harboring GAR (glycine- and arginine-rich) or PGM 
(proline-, glycine-, methionine-, arginine-rich) motifs are often candidate targets 
for PRMTs[69, 79].  
In contrast to the action of PRMTs, methylation of an arginine can be 
removed by demethylase or deiminase. JMJD6 (Jumonji domain–containing 6 
protein) is the only demethylase identified to data, which demethylates histone H3 
at arginine 2 and histone H4 at arginine 3, and reverses methylated arginine back 
to arginine[80]. Besides, the peptidyl arginine deiminase can block methylation on 
an arginine residue by converting it to citrulline. PAD4 (peptidylarginine deiminase 
4) deiminase has been shown to catalyze the deimination of both arginine and 
monomethylarginine, but not dimethylarginine, to citrulline and prevent 
dimethylation formation on histone H3 arginine 17 and histone H4 arginine 3 by 
PRMT4 and PRMT1, respectively[81] (Figure 3).  
 
1.5 PRMT5 
PRMT5 was originally cloned as a JAK2-binding protein with type II arginine 
methyltransferase activity[82, 83]. Subsequent investigations indicate that PRMT5 
functions in various protein complexes localized to both the cytoplasm and the  
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Figure 3. Inhibition of arginine methylation by the peptidyl arginine 
deiminase (PAD). PAD blocks arginine methylation by converting arginine or 
monomethyl arginine (MMA) to citrulline.  
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nucleus. Nuclear PRMT5 is linked to several roles in transcription regulation. It 
forms complexes with the hSWI/SNF (human switch/sucrose non-fermenting) 
chromatin-remodeling proteins BRG1 (Brahma-related gene 1) and BRM (Brahma) 
to methylate histone H3 at arginine 8, resulting in the repression of tumor 
suppressor genes ST7 (suppression of tumorigenicity 7) and NM23 
(nonmetastatic 23) and promotion of a tumorigenic state in NIH3T3 cells[84]. It 
also methylates histone H4 at arginine 3 to recruit DNA methyltransferase 
DNMT3A (DNA cytosine methyltransferase 3A) for gene silencing[85]. Besides, 
nuclear PRMT5-mediated arginine methylation of p53 disposes p53 to trigger 
cell-cycle arrest rather apoptosis[86]. In the cytoplasm, PRMT5 is found in the 
methylosome, where it methylates several spliceosomal Sm proteins to promote 
the assembly and stability of the splicesome and regulate snRNP 
(small nuclear ribonucleoprotein) biogenesis[87-89]. During the derivation of 
embryonic stem cells, PRMT5 is upregulated in the cytosol and methylates 
histone H2A at arginine 3 to maintain stem cell pluripotency[90]. In yeast model, 
cytoplasmic PRMT5 also has been shown to inhibit cell cycle progression through 
binding with cell cycle inhibitor cdc25p[91] and suppress the MAPK pathway by 
inhibiting STE20p kinase[92]. 
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Currently, little is known about the regulations of the expression, stability or 
activity of PRMT5. Recent studies indicate that PRMT5 activation requires 
PRMT5 homo-dimerization and association with a cofactor, Mep50 (methylosome 
protein 50)[68]. Moreover, the subcellular location of Mep50 varies under different 
physiological and pathological conditions[93-95]. These findings suggest that 
PRMT5 activity may be regulated by the expression or subcellular distribution of 
Mep50. In addition, tyrosine phosphorylation of PRMT5 by a JAK2 constitutively 
active mutant JAK2V617F disrupts PRMT5-Mep50 association and impairs 
PRMT5 methyltransferase activity[96]. Besides, the substrate specificity of 
PRMT5 can be regulated by its binding partners. RioK1 (Rio kinase 1) and pICln 
mutually exclusively bind with PRMT5. They complete for binding to PRMT5 and 
coexist with PRMT5-Mep50 in two distinct protein complexes, in which they serve 
as adapters to recruit different PRMT5 substrates. The RioK1-containing 
PRMT5-Mep50 complex methylates the RNA-binding protein nucleolin and the 
pICln-containing complex methylates the spliceosomal Sm proteins[97].  
 
1.6 Hypothesis  
Although protein arginine methylation and arginine methyltransferase have 
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been known since 1968[98, 99], the cellular processes affected by arginine 
methylation only have begun to be elucidates in the last decade, and a growing 
body of evidence suggests that methylation may parallel other PTMs in its role in 
the regulation of various biological processes[67, 68, 76, 77, 100, 101]. Here, we 
hypothesize that protein methylation may involve in the EGFR signaling, a 
biological process extensively regulated by multiple PTMs. If this is the case, 
identification and elucidation of the role of methylation in EGFR signaling will 
comprise a new level of EGFR regulation. 
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CHAPTER 2  MATERIAL AND METHOD 
 
2.1 Constructs, antibodies, reagents, and peptides 
All GFP-PRMT plasmids were kindly provided by Dr. Mark T. Bedford. 
PRMT3, PRMT5, and PRMT8 cDNAs were further subcloned into a modified 
pCMV5 vector containing an N-terminal HA tag. Full-length EGFR cDNA was 
cloned into a pCDNA3 vector. PRMT5 and EGFR intracellular domain (ICD, 
amino acid 645-1186) were further subcloned into a modified pCMV5 vector 
containing an N-terminal GST tag for the purification of recombinant protein. 
EGFR R1175K and PRMT5 R368A mutagenesises were generated using the 
QuickChange Site-Directed Mutagenesis Kit according to the manufacturer’s 
protocol (Stratagene). Epidermal growth factor (EGF) and U0126 were purchased 
from Sigma and Cell Signaling, respectively, and prepared according to the 
manufacturer’s instructions. The following peptides were chemically synthesized 
from QCB for antibody production in mice, dot blots, peptide competition assay, 
and in vitro methylation assay. Unmodified peptide: 
NH2-CAEYLRVAPQSSE-COOH; Methylated peptides: 
NH2-CAEYL(monomethyl-R)VAPQSSE-COOH, NH2-CAEYL(symmetric 
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dimethyl-R)VAPQSSE-COOH and NH2-CAEYL(asymmetric 
dimethyl-R)VAPQSSE-COOH. Histone H4 peptide with monomethyl R3 was 
purchased from Abcam. Anti-EGFR (Ab-12, 1:5000) antibody from Thermo 
Scientific and anti-EGFR (06-847, 1:5000) antibody from Millipore were used to 
detect full-length EGFR and EGFR peptides, respectively. For detection of EGFR 
tyrosine phosphorylations, antibody to phosphotyrosine (4G10, 1:5000) from 
Millipore was used to detect total tyrosine phosphorylations, and site-specific 
antibodies against phospho-Y845, Y992, Y1045, Y1068, Y1086, Y1148, and 
Y1173 from Cell Signaling and Abcam were used (1:2000) to detect individual 
phosphotyrosine. Antibodies to ERK (1:5000), SHP1 (1:2000) and SHC (1:5000) 
from Millipore, antibodies to STAT3 (1:2000) and SOS (1:2000) from Santa Cruz, 
and antibodies to AKT (1:2000), PLC-(1:2000), phospho-ERK (1:5000), 
phospho-AKT (1:2000), phospho-STAT3 (1:2000), phospho-PLC- (1:2000) and 
Grb2 (1:2000) from Cell Signaling were used to detect the EGFR downstream 
pathways. Anti-PRMT5 (1:5000) and anti-tubulin (1:5000) antibodies were from 
Sigma. Anti-GFP (1:5000) antibody was from Thermo Scientific. For 
immunofluorescence staining, antibodies were diluted 1:200. For 
immunoprecipitation, 5g of anti-EGFR (Ab-13, Thermo Scientific), anti-Grb2, 
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anti-SHC or anti-SOS antibodies were used per 1mg of total protein in 1 ml of cell 
lysates.  
 
2.2 In vivo methylation assay  
For in vivo methylation of EGFR, a procedure, modified from the method 
described by Qing Liu et al.[102], was used. A431 cells were incubated 1 hr in 
Dulbecco’s modified Eagle’s medium (DMEM) (GIBCO) supplemented with 10% 
FBS, 100 g/ml cycloheximide (Sigma), and 40 g/ml chloramphenicol (Sigma). 
Then, cells were washed twice with methionine-depleted DMEM (GIBCO) and 
incubated in the same medium containing 10 Ci/ml L-[methyl-3H]methionine 
(Amersham Biosciences), 10% dialyzed FBS (GIBCO), 100 g/ml cycloheximide, 
and 40 g/ml chloramphenicol. After labeling for 5 hr, endogenous EGFR was 
immunopurified and analyzed by SDS-PAGE. 3H-methyl incorporation was 
visualized by fluorography. For monitoring the effect of protein synthesis inhibitors, 
A431 cells were also labeled with 10 Ci/ml L-[35S]methionine (MP Biomedicals) 
using a procedure almost exactly the same as the one described above, with or 
without protein synthesis inhibitors. After labeling, whole-cell lysates were 
prepared, analyzed by SDS-PAGE, and detected by autoradiography.  
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2.3 In vitro methylation assay 
HA-PRMT3, HA-PRMT5, and HA-PRMT8 were expressed in HEK293 cells 
and immunopurified using HA-agarose (Sigma). The enzymes immobilized on the 
beads were then incubated with unmodified peptide (50 g) in the presence of 2.2 
Ci S-adenosyl-L-[methyl-3H]methionine (85 Ci/mmol from a 0.55 mCi/ml stock 
solution) (MP Biomedicals) for 1 hr at 30℃ in a final volume of 50 l of 
phosphate-buffered saline. One microgram of peptide was spotted onto PVDF 
membranes and detected using anti-EGFR or anti-EGFR me-R1175 antibodies. 
Five micrograms of peptide were spotted onto P81 papers, washed, and counted 
by liquid scintillation.  
In vitro methylation assay was also performed as following. GST-PRMT5 and 
GST-EGFR (ICD) were expressed in HEK293 cell and purified using glutathione 
resin (GE Healthcare). GST-PRMT5 and GST-EGFR (ICD) proteins were 
incubated in the presence of 2.2 Ci S-adenosyl-L-[methyl-3H]methionine (85 
Ci/mmol from a 0.55 mCi/ml stock solution) for 1 hr at 30℃ in a final volume of 50 
l of phosphate-buffered saline. Subsequently, samples were analyzed by 
SDS-PAGE and EGFR methylation was detected using fluorography and 
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anti-EGFR me-R1175 antibody.  
 
2.4 In vitro kinase assay  
A procedure, modified from the method described by Jaeho Lee et al.[103], 
was used. HA-EGFR was expressed in HEK293 cells and immunopurified using 
HA-agarose. The EGFR proteins immobilized on the beads were then incubated 
with unmodified or monomethylated peptides (50 g) in a total volume of 50 l of 
reaction buffer containing 5 mM HEPES (pH 7.4), 50 M Na3VO4, 5 mM MnCl2, 2 
mM MnCl2, 40 g/ml BSA, 250 mM ammonium sulfate, 25 M ATP, and 62.5 
Ci/ml [-32P]ATP (MP Biomedicals). Reactions were performed at 30℃ and 
stopped using 8.5% phosphoric acid. One microgram of peptide was spotted onto 
PVDF membranes and detected using anti-EGFR or anti-EGFR p-Y1173 
antibodies. Five micrograms of peptide were spotted onto P81 papers, washed, 
and counted by liquid scintillation. 
 
2.5 siRNA transfection and siRNA-resistant mutant of PRMT5  
Cells were transfected individually with three PRMT5 siRNA oligonucleotides 
(#1: 5’-UGGCACAACUUCCGGACUUUU-3’, #2: 
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5’-CAACAGAGAUCCUAUGAUU-3’ or #3: 5’-CGAAAUAGCUGACACACUA-3’) or 
two EGFR siRNA oligonucleotides (#1: 5’-CAAAGUGUGUAACGGAAUA-3’ or #2: 
5’-CCAUAAAUGCUACGAAUAU-3’) with DharmaFECT 1 (Dharmacon), and used 
for experiments 96 hr after transfection. A non-targeting siRNA 
(5’-UGGUUUACAUGUCGACUAA-3’) was used as control. To rescue the 
phenotype of PRMT5 siRNA, an siRNA-resistant mutant of PRMT5 (RR-PRMT5) 
was created by substituting five nucleotides in the PRMT5 siRNA #1 targeting 
region (C570T, C573T, C576T, C577A and G579A).  
 
2.6 Mass spectrometry  
EGFR was isolated by immunoprecipitation with anti-EGFR antibody and 
analyzed by SDS-PAGE. The protein band corresponding to EGFR was excised 
and subjected to in-gel digestion with trypsin. After being isolated from gel, 
samples were analyzed by nanoelectrospray mass spectrometry which was 
performed using an Ultimate capillary LC system (LC Packings, Amsterdam, The 
Netherlands) coupled to a QSTARXL quadrupole-time of flight (Q-TOF) mass 
spectrometer (Applied Biosystem/MDS Sciex, Foster City, CA). 
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2.7 Confocal microscopy analysis  
Cultured cells were washed three times with PBS, fixed in 4% 
paraformaldehyde for 15 min, permeabilized with 0.5% Triton X-100 for 15 min, 
and incubated with 5% bovine serum albumin for 1 h. Cells were then incubated 
with the primary antibodies overnight at 4°C. Cells were washed with PBS and 
then further incubated with the appropriate secondary antibody diluted at 1:500 
and tagged with fluorescein isothiocyanate (FITC), Texas red, or Alexa 647 [104] 
for 45 min at room temperature. Nuclei were stained with DAPI before mounting. 
Confocal fluorescence images were captured using a Zeiss LSM710 laser 
microscope. In all cases, optical sections through the middle planes of the nuclei 
as determined using nuclear counterstaining were obtained. 
 
2.8 Cell proliferation assay  
Cells (5 x 103 cells per well) were seeded in 96-well plates, and relative cell 
amounts were determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl- 
tetrazolium bromide (MTT) colorimetric method on a daily basis. MTT (Sigma) at 1 
mg/ml was added to each well. After 2-hr incubation, the medium was removed, 
and the MTT was solubilized in 100 l of DMSO. The absorbance was measured 
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at 570 nm, and the relative proliferation index for each day was determined using 
the absorbance at day 0 as the standard.  
 
2.9 Migration and invasion assay  
Cell migration and invasion were analyzed using Biocoat Control inserts and 
Biocoat Matrigel invasion chambers (BD Biosciences), respectively. Cells (2 x 105) 
in DMEM medium with 0.1% FBS were added to the upper chamber and allowed 
to penetrate a porous (8 m), uncoated membrane or a Matrigel-coated 
membrane to the bottom chamber containing DMEM medium with 10% FBS. 
Cells on the top surface of the membrane were removed 72 hr after incubation, 
and the remaining cells on the bottom surface were fixed with 4% 
paraformaldehyde, stained with 0.5 % crystal violet, and counted from four 
random fields of each membrane using a bright-field microscope. The average 
cell number per field for each membrane was used to calculate the mean and s.d. 
for triplicate membranes. Migration value is shown as “number of migrated cells 
per field”. Invasion value is reported as the “invasion index = number of invaded 
cells per field / number of migrated cells per field”.  
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2.10 Mouse model  
In vivo cell growth was analyzed in an orthotopic breast cancer mouse 
model[105]. Briefly, cells (5 x 106 cells) were injected into the mammary fat pads 
of nude mice, and the tumor volumes were measured weekly.  
 
2.11 Statistics  
All quantitative results are presented as the mean and s.d. of independent 
experiments. Statistical differences between two groups of data were analyzed by 
Student's t-test. 
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CHAPTER 3  EGFR R1175 IS MONOMETHYLATED 
 
3.1 EGFR is methylated in vivo 
To determine whether EGFR is a target of methylation, we performed an in 
vivo methylation assay in which cells were metabolically labeled with 
L-[methyl-3H]methionine in the presence of protein synthesis inhibitors (Figure 4A, 
lanes 1-6), and endogenous EGFR proteins were immunopurified, followed by 
analysis with fluorography. We observed a radioactive signal corresponding to the 
size of EGFR in the immuno-products of anti-EGFR antibody (Figure 4A, lane 2) 
but not in those of the control antibody (Figure 4A, lane 1). Simultaneously, we 
also labeled cells with L-[35S]methionine to monitor the activity of protein synthesis 
inhibitors (Figure 4A, lanes 7-10). No L-[35S]methionine incorporation was 
detected in the presence of the inhibitors (Figure 4A, compare lane 10 to lane 9), 
indicating that the radiolabeling in lane 2 was resulted from post-translational 
modification, rather than from translational incorporation. Taken together, these 
results suggest that endogenous EGFR is a target of protein methylation.  
 
3.2 EGFR R1175 is monomethylated 
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Next, we used mass spectrometry analysis to identify methylation site(s) of 
endogenous EGFR immunopurified from cells and result shows that EGFR R1175 
is monomethylated (Figure 4B). This finding further supports EGFR methylation 
and indicates methylation of R1175.  
 
3.3 Generation and characterization of the EGFR monomethylated-R1175 
antibody 
To assist detection of EGFR R1175 monomethylation, we generated a 
polyclonal antibody against a synthetic methylated EGFR peptide antigen. This 
antibody specifically recognized a monomethylated EGFR peptide (amino acid 
1171-1182), in which R1175 residue is monomethylated, but not unmodified and 
dimethylated peptides (Figure 5A). In addition, this antibody only recognized 
ectopic full-length EGFR wild type (wt) and not methylation-site mutant (R1175K) 
in cells (Figure 5B). In peptide competition assays, only the monomethylated 
EGFR peptide neutralized the activity of antibody (Figure 5C). Therefore, this 
antibody is capable of specifically recognizing R1175-methylated EGFR. In 
addition to exogenous EGFR proteins, this antibody is suitable for endogenous 
EGFR detection (Figures 5D and 5E). Methylated EGFR is mainly located at the 
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cell membrane region.  
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Figure 4. EGFR R1175 is monomethylated 
A. In vivo methylation of EGFR. A431 cells were metabolically labeled with 
L-[methyl-3H]methionine (left panel) or L-[35S]methionine (right panel) in the 
presence or absence of protein synthesis inhibitors, as indicated. 
Immunoprecipitates of EGFR or control antibodies from 
L-[methyl-3H]methionine-labeled cells were analyzed by fluorography (lanes 1 and 
2), coomassie blue staining (lanes 3 and 4), or western blotting with EGFR 
antibody (lanes 5 and 6). Whole-cell lysates of L-[35S]methionine-labeled cells 
were analyzed by coomassie blue staining (lanes 7 and 8) or autoradiography 
(lanes 9 and 10).  
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Figure 4. EGFR R1175 is monomethylated 
B. Mass spectrometry analysis of endogenous EGFR immunopurified from A431 
cells. 
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Figure 5. Generation and characterization of the antibody specifically 
recognizing EGFR R1175 methylation 
A. Amino acid sequence of peptides corresponding to the EGFR 1171-1182 
region in which R1175 is unmodified, monomethylated or dimethylated. Different 
amounts of peptides were spotted on PVDF membranes and detected by 
anti-EGFR (Millipore #06-847) or anti-EGFR me-R1175 antibodies.  
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Figure 5. Generation and characterization of the antibody specifically 
against EGFR R1175 methylation 
B. Western blot analysis of exogenous EGFR in HEK293 cells transfected with 
control vector, EGFR (wt) or EGFR (R1175K).  
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Figure 5. Generation and characterization of the antibody specifically 
against EGFR R1175 methylation 
C. Western blot analysis of exogenous EGFR in HEK293 cells transfected with 
empty vector, EGFR (wt) or EGFR (R1175K). Anti-EGFR me-R1175 antibody was 
pre-incubated with peptides, as indicated prior to use.  
 
 
D. Western blot analysis of endogenous EGFR in MDA-MB-468 cells transfected 
with control or EGFR siRNAs.  
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Figure 5. Generation and characterization of the antibody specifically 
against EGFR R1175 methylation 
E. Confocal microscopy analysis of MDA-MB-468 cells stained with total 
endogenous EGFR (red), me-R1175 (green) and DAPI (blue).  
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CHAPTER 4  PRMT5 METHYLATES EGFR R1175 IN VITRO AND IN VIVO 
 
4.1 PRMT5 interacts with EGFR and methylates R1175 
Members of the protein arginine methyltransferase (PRMT) family are the 
only enzymes responsible for protein arginine methylation[67]. To identify the 
upstream enzyme responsible for EGFR R1175 methylation, we screened the 
interaction between EGFR and several PRMT family members by using 
co-immunoprecipitation assays and found that EGFR bound with PRMT5 and 
PRMT8 (Figure 6A). Next, in vitro methylation assays were used to determine 
whether PRMT5 and/or PRMT8 could methylate EGFR. The unmodified EGFR 
peptide was incubated with affinity-purified PRMT3, PRMT5 or PRMT8 in the 
presence of S-adenosyl-L-[methyl-3H]methionine as a methyl donor and 
methylation was detected using R1175 methylation-specific antibody and 
scintillation counting. We observed that PRMT5 and PRMT8, but not PRMT3, 
methylated R1175 (Figure 6B). In human tissues, PRMT5 is ubiquitously 
expressed while PRMT8 is restricted in the brain [103, 106, 107]. In human breast 
cancer cell, EGFR is mainly associated with the cell membrane region, where 
some PRMT5 is also found (Figure 6C). Suppression of endogenous PRMT5 
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expression by short interfering RNAs (siRNAs) decreased R1175 methylation and 
reintroduction of an siRNA-resistant PRMT5 mutant (RR-PRMT5) rescued the 
effect of siRNA (Figure 6D). Collectively, these data indicate that PRMT5 is an 
enzyme responsible for EGFR R1175 methylation. Using in vitro methylation 
assays with recombinant EGFR proteins as substrates, we further confirmed that 
PRMT5 methylates EGFR only at R1175 residue (Figure 6E). 
 
4.2 EGF stimulation and EGFR kinase activity are not required for R1175 
methylation  
Similarly to the interactions between other PRMTs with their substrates[77, 
78, 106], PRMT5 binds with EGFR mainly through its catalytic core domain 
(Figure 7). Moreover, the PRMT5-EGFR binding (Figure 8, top panel) and the 
R1175 methylation status (Figure 8, bottom panel) are independent of EGF 
stimulation, indicating that EGF stimulation and EGFR kinase activity are not 
required for R1175 methylation.   
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Figure 6. PRMT5 interacts with EGFR and methylates R1175 
A. Western blot analysis of exogenous EGFR and PRMTs in the input and 
anti-EGFR immunoprecipitates from HEK293 cells transfected with EGFR and 
GFP-PRMTs, as indicated.  
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Figure 6. PRMT5 interacts with EGFR and methylates R1175 
B. In vitro methylation assay of unmodified EGFR peptide by immunopurified 
HA-PRMT3, 5, or 8. Methylation of peptides was detected by western blotting (top 
panel) and scintillation counting (bottom panel). Error bars represent s.d. (n = 3).  
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Figure 6. PRMT5 interacts with EGFR and methylates R1175 
C. Confocal microscopy analysis of MDA-MB-468 cells stained with endogenous 
EGFR (red), PRMT5 (green) and DAPI (blue).  
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Figure 6. PRMT5 interacts with EGFR and methylates R1175 
D. Western blot analysis of endogenous EGFR and total PRMT5 of the 
MDA-MB-468 cells in which endogenous PRMT5 was knocked down by three 
PRMT5 siRNAs (lane 1-4) and then rescued with an siRNA-resistant PRMT5 
mutant (RR-PRMT5) (lane 5). 
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Figure 6. PRMT5 interacts with EGFR and methylates R1175 
E. In vitro methylation assay of EGFR intracellular domain (ICD) wild type (wt) or 
R1175K mutant by PRMT5 wild type (wt) or inactive mutant (R368A). Methylation 
of EGFR (ICD) was detected by fluorography and western blotting using 
anti-EGFR me-R1175 antibody. 
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Figure 7. PRMT5 associates with EGFR through the catalytic core domain 
Left panel: Schematic representation of the PRMT5 domain structure containing 
catalytic core, pre-core and post-core domains. PRMT5 truncation mutants 
without pre-core domain, post-core domain or both domains are assigned as N, 
C or NC, respectively. Arabic numbers indicate amino acid residues. Right 
panel: Western blot analysis of exogenous EGFR and PRMT5 in the input and 
anti-EGFR immunoprecipitates from HEK293 cells transfected with EGFR and 
various PRMT5 truncation mutants. 
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Figure 8. EGF stimulation and EGFR kinase activity are not required for 
R1175 methylation 
Western blot analysis of endogenous EGFR and PRMT5 in the input (bottom 
panel) and immunoprecipitates of indicated antibodies (top panel) from 
EGF-stimulated and siRNA-transfected MDA-MB-468 cells. 
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CHAPTER 5  R1175 METHYLATION NEGATIVELY MODULATES EGFR 
FUNCTIONALITY 
 
5.1 Suppression of R1175 methylation promotes EGFR-mediated cell 
proliferation, migration, and invasion 
As mentioned in the introduction, multiple lines of the EGFR downstream 
signalings ultimately culminate in cell proliferation, migration, invasion, and 
tumorigenicity[14, 39, 40]. To investigate if EGFR R1175 methylation participates 
in the EGFR functionality, we created three stable transfectants of human MCF7 
breast cancer cells with EGFR (wt), EGFR (R1175K), or empty vector (designated 
as MCF7-EGFR [wt], MCF7-EGFR [R1175K], and MCF7-vector, respectively) for 
serial functional studies (Figure 9A). First, to evaluate their in vitro cell growth 
abilities, cells were cultured in DMEM supplemented with 10% FBS and relative 
cell amounts were determined by the MTT colorimetric method on a daily basis. 
The results showed MCF7-EGFR (R1175K) proliferated faster than MCF7-EGFR 
(wt), as compared with MCF7-vector control (Figure 9A). Moreover, we used an 
orthotopic tumor cell growth model to assay the in vivo cell growth of these cells. 
Cells were injected into the mammary fat pads of nude mice and the tumor 
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volumes were measured weekly. Consistently, we found that MCF7-EGFR 
(R1175K) cells were more efficient than MCF7-EGFR (wt) and MCF7-vector cells 
at inducing mammary tumor formation (Figure 9B). On the other hand, the cell 
motility or invasiveness of these cells was analyzed using a Transwell chamber 
system with a porous, uncoated membrane or a Matrigel-coated membrane 
respectively. The cells placed in the upper chamber were induced to migrate 
across 8.0 m membrane pores to the lower chamber in response to the 
chemoattractant. In cell motility, we observed EGFR (R1175K)-expressing cells 
migrated more efficiently than the control cells (220.2  46.6% of MCF7-vector 
control), even though MCF7-EGFR (wt) had only slightly positive effects on cell 
migration (132.8  24.8% of MCF7-vector control) under experimental condition 
(Figure 9C, left panel). In invasion assay, no significant effect was observed in 
MCF7-EGFR (wt) cells. In contrast, MCF7-EGFR (R1175K) cells exhibited 
significantly increased invasion ability (254.4  80.1% of MCF7-vector control) 
(Figure 9C, right panel). Taken together, these results suggest an inhibitory role of 
R1175 methylation in the EGFR functionality.  
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Figure 9. Suppression of R1175 methylation promotes EGFR-mediated cell 
proliferation, migration, and invasion 
A. Western blot analysis of MCF7 stable transfectants expressing EGFR (wt), 
EGFR (R1175K), or empty vector. In vitro cell proliferation rates were assayed 
using the MTT colorimetric method. Error bars represent s.d. (n = 5).  
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Figure 9. Suppression of R1175 methylation promotes EGFR-mediated cell 
proliferation, migration, and invasion 
B. In vivo cell proliferation was measured using an orthotopic breast cancer 
mouse model. Error bars represent s.d. (n = 10).  
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Figure 9. Suppression of R1175 methylation promotes EGFR-mediated cell 
proliferation, migration, and invasion 
C. Migration assay (left) and invasion assay (right) of these stable transfectants. 
Statistical analysis was performed with Student’s t-test. Error bars represent s.d. 
(n = 3).  
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CHAPTER 6  R1175 METHYLATION CROSSTALKS WITH Y1173 
PHOSPHORYLATION 
 
6.1 R1175 methylation upregulates ligand-stimulated EGFR 
autophosphorylation at Y1173 
Regulatory crosstalk usually occurs between two closely spaced 
post-translational modifications. To further explore how R1175 methylation is 
involved in EGFR functionality, we noticed that R1175 residue is close to several 
tyrosine residues that are autophosphorylated during EGFR activation. This gives 
us a clue that R1175 methylation might regulate EGFR through crosstalk with 
these tyrosine phosphorylations. Thus, we activated EGFR (wt) and EGFR 
(R1175K) with EGF and then compared their tyrosine phosphorylation status 
using several site-specific antibodies against phospho-Y845, Y992, Y1045, 
Y1068, Y1086, Y1148, and Y1173. Interestingly, compared with EGFR (wt), EGFR 
(R1175K) got fully phosphorylated at all tyrosine residues tested except Y1173 
(Figure 10A). To rule out the possibility that the change of Y1173 phosphorylation 
was caused by protein conformational misfolding of R1175K mutagenesis, EGFR 
R1175 methylation status was also manipulated by using multiple PRMT5 siRNAs 
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as a comparison. Consistently, PRMT5 knockdown specifically inhibited 
EGF-induced phosphorylation at Y1173, and not other tyrosine residues (Figure 
10B). These results indicate that R1175 methylation positively modulates Y1173 
phosphorylation.  
 
6.2 R1175 methylation upregulates Y1173 phosphorylation by EGFR in vitro 
EGFR Y1173 phosphorylation is mediated by EGFR itself. Thus, we further 
check whether R1175 methylation affects Y1173 phosphorylation by in vitro 
kinase assays in which EGFR peptides with or without R1175 monomethylation 
were used as substrates for EGFR. Results show EGFR phosphorylated the 
monomethylated peptide more efficiently than the unmodified peptide (Figure 11), 
further supporting previous finding that R1175 methylation upregulates Y1173 
phosphorylation.  
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Figure 10. R1175 methylation upregulates ligand-stimulated EGFR 
autophosphorylation at Y1173 
A. Left panel: Western blot analysis of exogenous EGFR in EGF-stimulated 
MCF7-EGFR (wt) and MCF7-EGFR (R1175K) stable transfectants. Right panel: 
Densitometry of phospho-EGFR Y1173 (p-Y1173) blot. Error bars represent s.d. 
(n = 3).  
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Figure 10. R1175 methylation upregulates ligand-stimulated EGFR 
autophosphorylation at Y1173 
B. Left panel: Western blot analysis of endogenous EGFR in EGF-stimulated 
MDA-MB-468 cells transfected with control or PRMT5 siRNA #1. Right panel: 
Densitometry of phospho-EGFR Y1173 (p-Y1173) blot. Error bars represent s.d. 
(n = 3).  
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Figure 11. R1175 methylation upregulates Y1173 phosphorylation by EGFR 
in vitro 
In vitro kinase assay of unmodified and monomethylated EGFR peptides by 
immunopurified EGFR proteins. Phosphorylation of peptides was detected by 
western blotting using anti-EGFR p-Y1173 antibody (top panel) and scintillation 
counting (bottom panel). Error bars represent s.d. (n = 3). 
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CHAPTER 7  CROSSTALK BETWEEN R1175 METHYLATION AND Y1173 
PHOSPHORYLATION RESULTS IN DOWNREGULATION OF ERK 
ACTIVATION 
 
7.1 Suppression of R1175 methylation inhibits SHP1 recruitment by EGFR  
During EGFR activation, phospho-Y1173 is one of the binding sites for the 
cytosolic signaling molecules SHC and Grb2 to elicit downstream ERK 
activation[108-110]. Phospho-Y1173 also serves as the major docking site for 
SHP1, an SH2 domain-containing protein tyrosine phosphatase. In contrast to the 
effect of SHC and Grb2 binding, recruitment of SHP1 to EGFR leads to 
attenuation of EGFR-dependent ERK activation[111]. Since R1175 methylation 
positively regulates Y1173 phosphorylation, we were motivated to investigate 
whether it modulates the binding between EGFR and these cytosolic molecules. 
Using a co-immunoprecipitation assay, we found that downregulation of R1175 
methylation by R1175K mutagenesis or by PRMT5 siRNA treatment inhibited only 
EGFR-SHP1 binding, and not EGFR-Grb2 and EGFR-SHC associations (Figures 
12A and 12B), suggesting that R1175 methylation improves SHP1 binding to 
EGFR and may inhibit EGFR-mediated ERK activation.  
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7.2 Suppression of R1175 methylation prolongs EGFR-mediated ERK 
activation 
We also studied the effect of EGFR R1175 methylation on the four major 
EGFR downstream pathways by monitoring the activation of key signaling 
molecules, including ERK1 (p-ERK1 T202/Y204) and ERK2 (p-ERK2 T185/Y187) 
in the RAS-RAF-MEK-ERK module, AKT (p-AKT S473) in the PI3K-AKT module, 
PLC-1 (p-PLC-1 T783) in the PLC--PKC module, and STAT3 (p-STAT3 T705) 
in the STATs module. In line with previous results, we observed that inhibition of 
R1175 methylation affected only EGFR-mediated activation of ERK, and not AKT, 
PLC- or STAT3 (Figures 13A and 13B). In EGFR (wt) cells, upon EGF stimulation, 
ERK activation was transiently upregulated and then rapidly deactivated. In 
contrast, ERK activation lasted longer when EGFR R1175 methylation was 
downregulated by R1175K mutagenesis or by PRMT5 siRNA transfection (Figures 
13A and 13B, compare even lanes and odd lanes). These results show that 
R1175 methylation specifically inhibits EGFR-mediated ERK activation. In 
supporting of this notion, ERK inhibitor treatment diminished the enhanced cell 
growth, migration, and invasion abilities of MCF7-EGFR (R1175K) cells (Figures 
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14A and 14B). 
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Figure 12. Suppression of R1175 methylation inhibits SHP1 recruitment by 
EGFR 
A. Left panel: Western blot analysis of EGFR, SHP1, Grb2 and SHC in the input 
and anti-EGFR immunoprecipitates from EGF-stimulated MCF7-EGFR (wt) and 
MCF7-EGFR (R1175K) stable transfectants. Right panel: Densitometry of 
EGFR-bound SHP1 blot. Error bars represent s.d. (n = 3).  
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Figure 12. Suppression of R1175 methylation inhibits SHP1 recruitment by 
EGFR 
B. Left panel: Western blot analysis of endogenous EGFR, PRMT5, SHP1, Grb2 
and SHC in the input and anti-EGFR immunoprecipitates from EGF-stimulated 
MDA-MB-468 cells transfected with control or PRMT5 siRNA #1. Right panel: 
Densitometry of EGFR-bound SHP1 blot. Error bars represent s.d. (n = 3).  
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Figure 13. Suppression of R1175 methylation prolongs EGFR-mediated ERK 
activation 
A. Left panel: Western blot analysis of endogenous ERK, PLC-, STAT3 and AKT 
in EGF-stimulated MCF7-EGFR (wt) and MCF7-EGFR (R1175K) stable 
transfectants. Right panel: Densitometry of phospho-ERK (p-ERK) blot. Error bars 
represent s.d. (n = 3).  
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Figure 13. Suppression of R1175 methylation prolongs EGFR-mediated ERK 
activation 
B. Left panel: Western blot analysis of endogenous EGFR, PRMT5, ERK, PLC-, 
STAT3 and AKT in EGF-stimulated MDA-MB-468 cells transfected with control or 
PRMT5 siRNA #1. Right panel: Densitometry of phospho-ERK (p-ERK) blot. Error 
bars represent s.d. (n = 3).  
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Figure 14. ERK inhibitor treatment impairs the enhanced cell growth, 
migration, and invasion abilities of MCF7-EGFR (R1175K) cells  
A. In vitro cell proliferation of MCF7-EGFR (wt), MCF7-EGFR (R1175K), and 
MCF7-vector cells were performed in the presence or absence of the ERK 
inhibitor U0126. Error bars represent s.d. (n = 3).  
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Figure 14. ERK inhibitor treatment impairs the enhanced cell growth, 
migration, and invasion abilities of MCF7-EGFR (R1175K) cells 
B. Migration (left) and invasion (right) assays of MCF7-EGFR (wt), MCF7-EGFR 
(R1175K), and MCF7-vector cells were performed in the presence or absence of 
the ERK inhibitor U0126. Error bars represent s.d. (n = 3).  
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CHAPTER 8  SUMMARY OF CHAPTER 3 TO 7 AND DISCUSSION 
 
We observe that PRMT5-mediated EGFR R1175 methylation (Figures 4, 5 
and 6) upregulates EGF-induced EGFR autophosphorylation at Y1173 (Figures 
10 and 11). This modification crosstalk positively modulates EGFR-SHP1 binding 
(Figure 12). In line with the published literatures[111], the increased EGFR-SHP1 
binding results in suppression of EGFR-mediated ERK activation (Figure 13). 
Accordingly, the methylation defective mutant, EGFR (R1175K), increases its 
activity to promote cell proliferation, migration, invasion and tumorigenicity (Figure 
9). Thus, we propose a new link between arginine methylation and tyrosine 
phosphorylation regulate EGFR functionality. This regulatory mechanism is 
significant for the following reasons. First, it indicates that EGFR methylation 
could differentially regulate the activation of EGFR downstream pathways. We 
might expect that any signaling event leading to a change in R1175 methylation 
status would specifically modulate the EGF-EGFR-ERK signaling axis. Second, it 
suggests EGFR might contain a protein modification code, which is reminiscent of 
the histone code composed of abundant cross-regulated histone 
modifications[112, 113]. In addition to R1175 methylation, seven potential lysine 
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and arginine methylation sites were also identified in the kinase domain and 
C-terminal tail of EGFR (Figure 15A). In the protein primary sequence, some of 
them are close to, or even overlap with, other known modifications (Figure 15B). 
Further study of individual methylation and their interrelationships with other 
modifications would expand our knowledge of the EGFR signaling network. In 
addition to EGFR, the current study may also open an avenue to understand the 
regulation of other receptor tyrosine kinases by arginine methylation.  
Our results suggest that EGFR Y1173 phosphorylation has a suppressive 
effect on ERK signaling. Previous literature gave phospho-Y1173 two opposite 
roles in EGFR-mediated ERK activation and indicated that phospho-Y1173 may 
coact with phospho-Y992 ,Y1068, Y1086 and Y1148 to activate ERK signaling 
through recruiting SHC and Grb2[108-110, 114], or may work alone to inhibit ERK 
activation through SHP1 binding[111]. However, to the best of our knowledge, the 
interrelationships between these two groups of proteins and phospho-Y1173 have 
not been well-characterized. Here, we first demonstrate that EGFR recruits these 
two groups of signaling molecules in a time-dependent manner (Figure 12). Upon 
EGF stimulation, SHC and Grb2 bind to EGFR immediately while SHP1 is 
recruited to EGFR only at the later stage (~30 min later after stimulation). 
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Downregulation of phospho-Y1173 only suppresses the recruitment of SHP1 but 
not SHC and Grb2 (Figure 12). These results indicate that the major function of 
phospho-Y1173 is recruiting SHP1 to deactivate ERK at the later stage of EGFR 
activation instead of recruiting SHC and Grb2 for ERK activation, which, as 
mentioned above[108-110, 114], is coregulated by multiple phosphotyrosine 
residues. The minor influence of Y1173 phosphorylation on SHC and Grb2 
recruitment could be due to the redundancy in both specificity and function of the 
different EGFR phosphorylation sites[38, 39]. To further address the role of 
phospho-Y1173 in ERK activation, we generated a MCF7-EGFR (Y1173F) stable 
transfectant and found that it exhibited higher proliferation and tumor formation 
abilities than the MCF7-EGFR (wt) cells (Figures 16A, 16B and 16C), supporting 
the suggestion that Y1173 phosphorylation plays a suppressive role in EGFR 
functionality. 
The association of SHP1 with EGFR results in suppression of 
EGFR-mediated ERK activation. However, present knowledge has different 
interpretations of the action of SHP1 on the EGFR signaling such that SHP1 
binding to the EGFR can cause an overall decrease in tyrosine phosphorylation 
status of the receptor and attenuation of the receptor signaling both in transient 
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coexpression systems and in stably SHP1-transfected cells[111, 115, 116]. 
However, other studies have shown that repression of endogenous SHP1 
expression by SHP1 siRNA does not affect full EGFR tyrosine 
phosphorylation[117]. This contradiction raises question of how endogenous 
SHP1 is involved in the EGFR signaling regulation. To clarify this issue, we 
knocked down endogenous SHP1 expression by SHP1 siRNA and examined its 
effect on EGF-stimulated EGFR phosphorylation and downstream signaling 
activation (Figure 17A). The results show that SHP1 knockdown extends ERK 
activation and, in line with previous studies, does not affect the EGFR tyrosine 
phosphorylation status, suggesting that endogenous SHP1 may dephosphorylate 
other molecules rather than EGFR to attenuate ERK activation.  
EGFR activates ERK through EGFR-SHC-Grb2-SOS-Ras-RAF-MEK-ERK 
pathway. Upon EGF stimulation, SHC-Grb2-SOS complex is recruited to EGFR. It 
has been reported that these three molecules are subject to tyrosine 
phosphorylation[118-120]. Next, we tested whether they are potential targets of 
SHP1. We found EGF stimulation induces tyrosine phosphorylation of SHC and 
SOS and knockdown of endogenous SHP1 can extend the phosphorylation status 
of SOS (Figure 17B), suggesting SOS may be a potential target of endogenous 
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SHP1 to reduce the activity of ERK. Given that phospho-Y1173 is the major 
binding site of SHP1, we further tested whether Y1173 is involved in the regulation 
of SOS tyrosine phosphorylation and found SOS phosphorylation status lasted 
longer in the EGFR (Y1173F) cells than in the EGFR (wt) cells (Figure 17C). 
Taken together, these data imply that phospho-Y1173 recruits endogenous SHP1 
to attenuate ERK activation through reducing the phosphorylation of SOS, rather 
than EGFR. Moreover, a similar pattern also could be observed in the EGFR 
(R1175K) cells (Figure 17C), further supporting that R1175 methylation 
downregulates ERK activation through enhancing Y1173 phosphorylation. 
In this study, we found that EGFR R1175 methylation status is consistent 
during EGF stimulation, raising question of how EGFR R1175 methylation can be 
regulated. During our manuscript preparation, other studies indicate that the 
methyltransferase activity of PRMT5 is controlled by Mep50. Mep50 is first 
identified as an interacting protein of PRMT5 from a yeast-two hybrid screening 
and subsequent studies show that Mep50 binding to PRMT5 is required for the 
methyltransferase activity of PRMT5[68, 121]. Moreover, Mep50 has different 
subcellular distribution patterns at various pathological stages of breast 
cancer[122]. In malignant breast epithelia, Mep50 prefers nuclear localization, 
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whereas in their benign counterparts, Mep50 is located at cytoplasm. Cytoplasmic 
Mep50 has been linked to cell growth inhibition[122], but the mechanism is 
unclear. As our results indicate PRMT5 methylates EGFR and suppresses 
EGFR-mediated cell growth, it is reasonable to predict that cytoplasmic Mep50 
may inhibit cell growth through upregulating PRMT5-mediated EGFR methylation. 
To verify this hypothesis, we first tested whether cytoplasmic Mep50 is involved in 
EGFR methylation. Following the method used in the original study[122], we 
observed that NES (nuclear exporting signal)-fused Mep50, rather than NLS 
(nuclear localization signal)-fused Mep50, increased EGFR R1175 methylation in 
human breast cancer cell (Figure 18A), suggesting cytoplasmic Mep50 is involved 
in EGFR R1175 methylation. Next, we evaluated the effect of EGFR methylation 
in cytoplasmic Mep50-mediated cell growth suppression and found that 
MCF7-EGFR (wt) cells were more susceptible than MCF7-EGFR (R1175K) cells 
to NES-Mep50-induced cell growth arrest (Figure 18B), implying cytoplasmic 
Mep50 may suppress cell growth through upregulating EGFR R1175 methylation. 
Taken together, these preliminary data imply that the subcellular distribution of 
Mep50 is a regulatory factor for EGFR R1175 methylation and future work will be 
directed towards elucidation of the role of EGFR methylation at different 
 67
pathological stages of breast cancer. 
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Figure 15. Summary of EGFR post-translational modifications 
A. Mass spectrometry identification of EGFR methylation sites. In addition to 
R1175 monomethylation, another seven potential EGFR methylation sites were 
identified in our mass spectrometry analysis, including one dimethylated lysine 
(K704), three monomethylated lysines (K713, K946 and K1037), two 
monomethylated arginines (R752 and R962) and one dimethylated arginine 
(R1076).  
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Figure 15. Summary of EGFR post-translational modifications 
B. Schematic representation of the functional domains of EGFR intracellular 
domain (amino acid 645-1186), including a juxtamembrane domain (JM, amino 
acid 645-683), a tyrosine kinase domain (KD, amino acid 683-959) and a 
C-terminal tail region (CT, amino acid 959-1186). The relative positions of known 
EGFR post-translational modifications[10, 64], including phosphorylation (P), 
ubiquitination (U), acetylation (A) and also the methylation (M) sites we identified 
are indicated. Alphabets indicate the amino acid residues subjected to 
modifications (T, threonine; S, serine; Y, tyrosine; K, lysine; R, arginine). Arabic 
numbers indicate amino acid positions.  
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Figure 16. MCF7-EGFR (Y1173F) cells exhibit lower cell growth and tumor 
formation abilities than MCF7-EGFR (wt) cells 
A. Western blot analysis of MCF7 stable transfectants expressing EGFR (wt), 
EGFR (Y1173F), EGFR (R1175K) or empty vector.  
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Figure 16. MCF7-EGFR (Y1173F) cells exhibit lower cell growth and tumor 
formation abilities than MCF7-EGFR (wt) cells 
B. In vitro cell proliferation assay of the stable transfectants using the MTT 
colorimetric method. Error bars represent s.d. (n = 5).  
 
C. In vivo cell proliferation of the stable transfectants in an orthotopic breast 
cancer mouse model. Error bars represent s.d. (n = 10).  
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Figure 17. Knockdown of endogenous SHP1 enhances EGF-stimulated SOS 
phosphorylation and ERK activation 
A. Western blot analysis of endogenous EGFR, ERK and AKT in EGF-stimulated 
MDA-MB-468 cells transfected with control or SHP1 siRNA.  
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Figure 17. Knockdown of endogenous SHP1 enhances EGF-stimulated SOS 
phosphorylation and ERK activation 
B. Western blot analysis of the tyrosine phosphorylation status of SOS, SHC and 
Grb2 immunoprecipitated from EGF-stimulated MDA-MB-468 cells transfected 
with control or SHP1 siRNA.  
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Figure 17. Knockdown of endogenous SHP1 enhances EGF-stimulated SOS 
phosphorylation and ERK activation 
C. Western blot analysis of the tyrosine phosphorylation status of SOS, SHC and 
Grb2 immunoprecipitated from EGF-stimulated MCF7-EGFR (wt), MCF7-EGFR 
(Y1173F) and MCF7-EGFR (R1175K) stable transfectants.  
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Figure 18. Expression of cytosolic Mep50 enhances R1175 methylation and 
inhibits cell growth 
A. Western blot analysis of EGFR and Mep50 in the MCF7-EGFR (wt) cells 
ectopically expressed with NES (nuclear exporting signal)-fused Mep50, NLS 
(nuclear localization signal)-fused Mep50, or empty vector.  
 
B. In vitro cell proliferation assay of the MCF7-EGFR stable transfectants 
expressed with NES-Mep50 or vector. Error bars represent s.d. (n = 5). 
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CHAPTER 9  FUTURE DIRECTIONS 
 
9.1 Further elucidation of the functions of individual methylations or the 
interrelationships between methylations and other modifications 
In addition to R1175 methylation, several methylation sites are also identified 
in current study, some of which are close to, or even overlap with, other known 
modifications that play critical roles in the regulation of EGFR functionalities 
(Figure 15). This suggests that protein methylation may have more in-depth 
participation in the EGFR signaling and this field is worthwhile to be pursued 
further to make the EGFR signalosome more comprehensive.  
 
9.2 Identification of the regulatory mechanism and physiological relevance 
of EGFR R1175 methylation 
Our current study shows that EGFR R1175 methylation is involved in the 
downstream ERK activation. However, it is still unclear clear what kind of 
extracellular stimulus can lead to change of the EGFR methylation status and 
which type of biological process is regulated by EGFR methylation. Our data imply 
that EGFR R1175 methylation could be controlled by the cytoplasmic distribution 
 77
of Mep50 (Figure 18) and may involve in the regulation of breast cancer cell 
growth in different pathological stages. The role of EGFR methylation in breast 
cancer progression will be further studied.  
In addition, EGFR methylation might also involve in the proliferation and 
differentiation of stem cells. In Drosophila models, EGFR-RAS-ERK and 
JAK-STAT pathways are identified as two important participants in mediating 
intestinal stem cell proliferation and differentiation and maintaining midgut 
epithelial homeostasis in response to damage or stress[123, 124]. Later studies 
indicate that these two signalings work cooperatively. JAK-STAT pathway-induced 
stem cell proliferation is dependent on EGFR signaling[125], but the 
exact mechanism is unclear. Recently, two separate studies reveal that 
PRMT5-Mep50 complex suppresses embryonic stem cell differentiation[90] and 
JAK2V617F, a constitutively active mutant of JAK2, promotes hematopoietic stem 
cell proliferation and differentiation through phosphorylating PRMT5, disrupting 
PRMT5-Mep50 association and inactivating PRMT5[96]. Moreover, our finding 
show that PRMT5-mediated EGFR methylation is a negative modulator of 
EGFR-RAS-ERK signaling. Taken all these results together, we predict that EGFR 
methylation might be regulated by JAK2 phosphorylation-mediated PRMT5 
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inactivation and involve in the regulation of stem cell proliferation and 
differentiation (Figure 19). 
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Figure 19. Potential connections between JAK2 signaling, EGFR signaling 
and PRMT5-Mep50 complex in regulating stem cell proliferation and 
differentiation.  
The PRMT5-Mep50 complex methylates EGFR and inhibits EGFR-mediated ERK 
activation. JAK2 kinase may activate the EGFR-ERK pathway through directly 
phosphorylating EGFR, or disrupting the association between PRMT5 and 
Mep50. 
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